Alterity Therapeutics (ASX:ATH)

Company Profile

Alterity Therapeutics is a late-clinical stage biotechnology company focused on developing disease modifying therapies for neurodegenerative diseases. Alterity’s first indication is Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder with no approved therapy. In a randomized, double-blind, placebo controlled P2 trial, ATH434 demonstrated robust efficacy on the key clinical endpoint, target engagement, and a favorable safety profile. ATH434 is a small molecule drug candidate which has been granted U.S. FDA Fast Track Designation and has also received Orphan Drug Designation in both the U.S. and Europe for the treatment of MSA.

 

Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is led by an experienced leadership team with multiple FDA approvals in neurology. Alterity is based in San Francisco, California, and Melbourne, Australia. 

KEY PEOPLE

Dr. David Stamler

CEO

David Stamler, M.D. became CEO of Alterity in January 2021 after serving as their Chief Medical Officer since 2017. He has over 30 years of pharmaceutical experience, including senior roles at Teva, Auspex, XenoPort, and Abbott Laboratories, specializing in clinical development and neurological disorders. Dr. Stamler received an M.D. from the University of Chicago—The Pritzker School of Medicine and a B.A. in Biology from the University of Chicago.

Margaret Bradbury, Ph.D.

Vice President, Research and Non Clinical

Margaret, Ph.D., has over 18 years of experience in the biotech and pharmaceutical industries, leading successful projects and teams in pharmacology, pharmacokinetics and toxicology. Prior to joining Alterity she was a Senior Director at Teva Pharmaceuticals and an Executive Director at Auspex Pharmaceuticals.  During her tenure she guided the nonclinical studies leading to FDA’s approval of Austedo®, the first approved deuterium-substituted small molecule drug.  Prior to Teva, Margaret was Associate Director of Neuroscience Research at Neurocrine Biosciences and led various projects at Merck Research Laboratories.

Cynthia Wong, M.P.H

Vice President, Clinical Operations

Cynthia Wong, M.P.H heads Clinical Operations at Alterity. Prior to joining Alterity, Cynthia held multiple clinical operations leadership roles at Auspex and Teva, including leading clinical trial activities for the registration study of AUSTEDO in Huntington Disease chorea. Prior to this, Cynthia led Phase 1-3 studies, including registration studies for marketing approval for Quillichew ER, Esbriet and Infergen.

RELATED STOCKHEAD STORIES